



## Artivion to Participate in Upcoming Investor Conferences

August 3, 2022

ATLANTA, Aug. 3, 2022 /PRNewswire/ -- **Artivion, Inc. (NYSE: AORT)**, a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.



Artivion's management team will present at the upcoming Canaccord Genuity 42<sup>nd</sup> Annual Growth Conference on Thursday, August 11, 2022 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 9:30 a.m. ET. A live webcast can be accessed through Artivion's website, [www.artivion.com](http://www.artivion.com), on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.

Members of the management team will also participate in the 7<sup>th</sup> Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Monday, August 15, 2022 & Tuesday, August 16, 2022. Due to the format of this event no webcast will be available.

### About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, [www.artivion.com](http://www.artivion.com).

#### Contacts:

##### Artivion

D. Ashley Lee  
Executive Vice President &  
Chief Financial Officer  
Phone: 770-419-3355

##### Gilmartin Group LLC

Brian Johnston / Lynn Lewis  
Phone: 332-895-3222  
[investors@artivion.com](mailto:investors@artivion.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/artivion-to-participate-in-upcoming-investor-conferences-301598835.html>

SOURCE Artivion, Inc.